Kyverna Therapeutics, Inc.
KYTX
$7.18
$0.629.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -14.96% | -4.32% | |||
| Gross Profit | 14.96% | 4.32% | |||
| SG&A Expenses | -3.77% | -13.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.80% | -6.32% | |||
| Operating Income | 12.80% | 6.32% | |||
| Income Before Tax | 12.58% | 5.72% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.58% | 5.72% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.58% | 5.72% | |||
| EBIT | 12.80% | 6.32% | |||
| EBITDA | 13.31% | 5.41% | |||
| EPS Basic | 12.96% | 5.74% | |||
| Normalized Basic EPS | 12.97% | 5.73% | |||
| EPS Diluted | 12.96% | 5.74% | |||
| Normalized Diluted EPS | 12.97% | 5.73% | |||
| Average Basic Shares Outstanding | 0.44% | 0.02% | |||
| Average Diluted Shares Outstanding | 0.44% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||